scispace - formally typeset
L

Luis M. Ruilope

Researcher at European University of Madrid

Publications -  891
Citations -  109166

Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.

Papers
More filters
Journal ArticleDOI

Resistant hypertension and renal denervation. Considerations on the results of the SYMPLICITY HTN-3 trial.

TL;DR: The SYMPLICITY HTN-3 trial as mentioned in this paper is a randomized, single-blind, randomized, sham-controlled trial, which concluded that RDN is safe, but apparently lacks efficacy.
Journal ArticleDOI

Detection and treatment of resistant hypertension.

TL;DR: The evaluation of patients with resistant hypertension should be directed toward confirming true treatment resistance, identifying the causes contributing to treatment resistance (including secondary causes of hypertension), and documenting target-organ damage.
Journal ArticleDOI

Renin-angiotensin system blockade: time for a reappraisal?

TL;DR: This editorial refers to ‘Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial’, by K.K.Teo et al, as an example, either alone or in combination, these drugs are prescribed in > 30–40% of the hypertensive population.
Journal ArticleDOI

Expertise: No Longer a Sine Qua Non for Guideline Authors?

TL;DR: The Free Dictionary defines expertise as "special skills or knowledge acquired by a person through education, training, or experience" as mentioned in this paper, which can be used to assess the quality and quantity of expertise of a guideline author.
Journal ArticleDOI

Lipophilic dihydropyridines provide renal protection from cyclosporin toxicity.

TL;DR: Calcium Antagonists can provide renal protection in patients who undergo renal cadaveric transplantation and are treated with cyclosporin and Lacidipine, a lipopholic dihydropyridine calcium antagonist, prevents the reductions in the glomerular filtration rate and renal plasma flow that are often seen after cyclospora A administration.